<DOC>
	<DOCNO>NCT02496676</DOCNO>
	<brief_summary>Background : - X-linked immunodeficiency magnesium defect , Epstein-Barr virus infection , neoplasia syndrome call XMEN syndrome . In genetic condition , cell less magnesium normal . This make hard body fight infection . Researchers want see magnesium supplement make easy body fight infection . Objective : - To see magnesium supplement strengthen immune system reduce amount Epstein-Barr virus people XMEN syndrome . Eligibility : - People age 6 old XMEN syndrome Design : - Participants screen : - Medical history - Physical exam - CT scan : Participants drink contrast may get dye IV arm . They lie machine take picture body . - EKG : Small sticky patch body trace heart rhythm . - Blood test - The study 2 part . - Participants part participate 1 year visit clinic 15 &lt; TAB &gt; time . These visit include physical exam blood urine test . - Participants first part finish 6 month few visit . - For study part 1 , participant take magnesium pill 3 month placebo pill another 3 month . - At 3 6 month , physical exam , medical history , blood urine test , &lt; TAB &gt; EKG . - If magnesium pill helpful , participant study part 2 . - They admit hospital 4 5 day get magnesium 3 day arm vein . - They take magnesium pill another 6 month .</brief_summary>
	<brief_title>Magnesium Supplementation People With XMEN Syndrome</brief_title>
	<detailed_description>X-linked immunodeficiency magnesium defect , Epstein-Barr virus ( EBV ) infection neoplasia ( XMEN ) syndrome primary immunodeficiency cause loss expression magnesium transporter 1 ( MAGT1 ) . This syndrome associate CD4 lymphopenia , chronic EBV infection , EBV-related lymphoproliferative disorder . The loss MAGT1 lead impaired T cell activation decrease expression activator receptor , NKG2D natural killer ( NK ) cell CD8 T cell , lead decrease EBV-specific cytolytic function cell . Results previous study suggest magnesium supplementation may viable therapeutic option patient XMEN . The propose study 2 part . Part I randomize , double-blind , placebo-controlled , crossover study evaluate safety efficacy oral magnesium L-threonate patient XMEN syndrome . Patients randomize receive escalating dos either placebo oral magnesium L-threonate 12 week . Patients receive crossover treatment ( magnesium placebo ) additional 12 week . For patient experience 0.5-log decrease number EBV-infected B cell oral magnesium compare placebo , study complete . Patients meet outcome undergo 2-week washout period proceed Part II , open-label , non-randomized evaluation intravenous magnesium sulfate ( MgSO4 ) follow oral magnesium L-threonate . These patient hospitalize receive 3 day intravenous MgSO4 3 daily dos total 30 mg/kg/day . They restart escalate dos oral magnesium L-threonate continue remain 24 week Part II . Efficacy assess change absolute number EBV-infected B cell follow treatment placebo . If conduct , Part II allow secondary analysis compare different duration magnesium supplementation .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>INCLUSION CRITERIA : All follow inclusion criterion must meet prior enrollment : 1 . Molecular diagnosis MAGT1 genetic defect 2 . Documented persistent EBV viral load ( great equal 5,000 copies/mL blood EBV log great equal 3.7 IU/mL ) define 2 positive determination least 3 month apart within 1 year enrollment 3 . Greater equal 6 year year age 4 . Willingness stop magnesium supplement ( study agent ) multivitamins overthe countersupplements may contain magnesium duration study 5 . Willingness go without magnesium supplementation 12week placebo period 2week washout period ( prestudy midstudy ) 6 . Willingness sample store future research 7 . Must physician home followup care EXCLUSION CRITERIA : 1 . Chemotherapy radiotherapy lymphoma within 12 month prior enrollment 2 . Rituximab exposure within 6 month prior enrollment 3 . Systemic symptom suggestive evolve lymphoma 4 . History clinically significant cardiac arrhythmia cardiac defect 5 . Renal insufficiency ( calculated creatinine clearance &lt; 50 mL/min insufficiency require dialysis ) 6 . Advanced heart block 7 . Hypermagnesemia , define magnesium serum concentration &gt; 2 mmol/L ( &gt; 5 mg/dL ) 8 . Human immunodeficiency virus ( HIV ) seropositivity 9 . Signs symptoms lifethreatening active microbial infection 10 . History hypersensitivity study agent 11 . Any condition , investigator opinion , may substantially increase risk associate study participation compromise study scientific objectives 12 . Participation clinical protocol include intervention , opinion investigator , may affect result current study</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 14, 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Epstein-Barr Virus</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>MAGT1 Gene</keyword>
	<keyword>Intracellular Magnesium</keyword>
</DOC>